Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from SinoMab Bioscience Ltd. ( (HK:3681) ).
SinoMab BioScience Limited has successfully completed the subscription of new shares under a general mandate, issuing a total of 112,810,817 shares. This issuance represents approximately 9.37% of the company’s enlarged share capital and has raised net proceeds of about HK$123,956,911, which will be used as previously disclosed. This move is expected to impact the company’s shareholding structure and potentially enhance its financial position and market presence.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, focusing on the development and commercialization of therapeutics for the treatment of immunological diseases. The company is involved in the research and development of monoclonal antibody-based biologics.
Average Trading Volume: 553,893
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.32B
For an in-depth examination of 3681 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue